Filing Details

Accession Number:
0000874015-23-000226
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-12-18 16:55:42
Reporting Period:
2023-12-14
Accepted Time:
2023-12-18 16:55:42
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
874015 Ionis Pharmaceuticals Inc IONS Pharmaceutical Preparations (2834) 330336973
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1073387 Frank C Bennett 2855 Gazelle Court
Carlsbad CA 92010
Evp, Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-12-14 14,002 $47.34 79,756 No 4 M Direct
Common Stock Disposition 2023-12-14 14,002 $49.21 65,754 No 4 S Direct
Common Stock Acquisiton 2023-12-14 8,610 $47.34 74,364 No 4 M Direct
Common Stock Disposition 2023-12-14 8,610 $50.19 65,754 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2023-12-14 14,002 $0.00 14,002 $47.34
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2023-12-14 8,610 $0.00 8,610 $47.34
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
31,223 2018-01-03 2024-01-02 No 4 M Direct
22,613 2018-01-03 2024-01-02 No 4 M Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.75 to $49.75 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) on this Form 4.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.50 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.